JOURNAL OF RHEUMATOLOGY, cilt.34, sa.3, ss.474-480, 2007 (SCI-Expanded)
Objective. Tuberculin skin testing with purified protein derivative (PPD) is part of tuberculosis (TB) screening in patients receiving infliximab. We assessed whether infliximab, a strong inhibitor of inflammation, suppressed dermal induration, the outcome of this test. We also reassessed the booster phenomenon and the interobserver variability in tuberculin testing.